Saccharomyces boulardii için Traveler's Diarrhea
BRCTs show 25-40% reduction in traveler's diarrhea when started 5 days before travel. Effects vary by destination.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dsaccharomyces\u002Dboulardii\u0026condition\u003Dtravelers\u002Ddiarrhea';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
Sonuç
RCTs show 25-40% reduction in traveler's diarrhea when started 5 days before travel. Effects vary by destination.
Key Study Findings
Meta-Analysis
Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.
Dose: None
vs: placebo
Outcome: improvement in key IBS symptoms
Etki: None
None
Popülasyon: patients with IBS from 32 RCTs evaluating 10 probiotic strains
Randomized Controlled Trial
n=47
8 weeks
Double-blind
Effects of a polyphenol-rich extract blend, probiotics, and hydrolyzed fiber on quality of life and …
Dose: None
vs: Placebo (Group I) and partial formulation (Group II)
Outcome: IBS quality of life (QoL questionnaire)
Etki: Dysphoria: median diff -5 (Group III) vs -1 (contr
0.0021 (dysphoria Group III)
Popülasyon: Patients with IBS
Other
Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and …
Dose: None
vs: None
Outcome: Clinical guideline recommendations for pediatric GI
Etki: None
None
Popülasyon: Pediatric patients with GI disorders
Observational Study
n=279
Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care …
Dose: None
vs: None
Outcome: Probiotic prescribing habits of Italian PCPs
Etki: L. rhamnosus GG used by 91.8%
None
Popülasyon: Italian primary care pediatricians
Other
n=70
16 weeks
Open-label
Synbiotic Supplementation for Chronic Constipation in Patients Under Peritoneal Dialysis: An Italian Multicenter Prospective Study.
Dose: None
vs: None (single-arm study)
Outcome: Constipation scoring system change
Etki: -5.3 (95% CI -5.9/-4.7)
0.001
Popülasyon: Peritoneal dialysis patients with chronic constipation
Review
An update on probiotics in paediatrics.
Dose: None
vs: None
Outcome: GI disorder outcomes in paediatrics
Etki: None
None
Popülasyon: Paediatric patients with GI disorders
Key Statistics
4
Çalışmalar
3200
Katılımcılar
↑
Positive
B
Derece
Referenced Papers
Journal of clinical …
2026
Probiotics and antimicrobial …
2025
26 atıf
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Review
Journal of gastroenterology …
2025
10 atıf
Frontiers in cellular …
2025
3 atıf
Frontiers in nutrition
2025
3 atıf
Journal of renal …
2025
Antibiotics (Basel, Switzerland)
2025
Boletin medico del …
2025
Current opinion in …
2025
Open forum infectious …
2024
7 atıf
Zhongguo dang dai …
2024
5 atıf
Advances in experimental …
2024
2 atıf
Therapeutic advances in …
2023
97 atıf
Overview of systematic reviews of probiotics in the prevention and treatment of antibiotic-associated diarrhea in children.
Systematic Review
Frontiers in pharmacology
2023
20 atıf
Cureus
2023
19 atıf
Cureus
2023
5 atıf
The Journal of …
2023
1 atıf
Archivos argentinos de …
2022
23 atıf
Physiology & behavior
2021
35 atıf
Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections.
Review
World journal of …
2019
92 atıf
Probiotics and antimicrobial …
2019
43 atıf
Applied microbiology and …
2019
25 atıf
Advances in experimental …
2019
17 atıf
Frontiers in medicine
2018
450 atıf
Choosing an appropriate probiotic product for your patient: An evidence-based practical guide.
Systematic Review
PloS one
2018
205 atıf
Pharmacological research
2018
132 atıf
PloS one
2018
76 atıf
World journal of …
2018
52 atıf
The American journal …
2018
46 atıf
Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders.
Review
British journal of …
2017
145 atıf
European journal of …
2017
93 atıf
World journal of …
2017
68 atıf
Pediatric gastroenterology, hepatology …
2017
42 atıf
Journal of pediatric …
2016
233 atıf
Clinical and experimental …
2016
82 atıf
Open forum infectious …
2016
58 atıf
Digestive diseases (Basel, …
2016
37 atıf
The Cochrane database …
2015
233 atıf
Antibiotics (Basel, Switzerland)
2015
104 atıf
Journal of clinical …
2015
35 atıf
Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children.
Review
Nutrition in clinical …
2015
31 atıf
Nutricion hospitalaria
2015
5 atıf
MMW Fortschritte der …
2014
14 atıf
MMW Fortschritte der …
2014
3 atıf
Expert opinion on …
2014
Frontiers in immunology
2013
263 atıf
The American journal …
2012
104 atıf
Saccharomyces boulardii and antibiotic-associated diarrhea: effectiveness of prophylactic use.
Other
The American journal …
2012
5 atıf
Medycyna wieku rozwojowego
2012
1 atıf
Journal of clinical …
2011
432 atıf
World journal of …
2010
512 atıf
Digestive diseases and …
2010
45 atıf
Journal for specialists …
2010
22 atıf
Probiotics.
Review
American journal of …
2010
European journal of …
2009
91 atıf
Current opinion in …
2009
82 atıf
Advances in biochemical …
2008
535 atıf
Probiotics.
Review
American family physician
2008
Journal of clinical …
2008
The Journal of …
2007
265 atıf
Nutrition (Burbank, Los …
2007
39 atıf
The Cochrane database …
2007
The American journal …
2006
918 atıf
Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials.
Meta-Analysis
CMAJ : Canadian …
2006
197 atıf
Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea.
Review
Journal of clinical …
2006
112 atıf
Medical science monitor …
2006
The American journal …
2001
648 atıf
International journal of …
2000
181 atıf
Clinical infectious diseases …
1998
346 atıf
Anaerobe
1997
40 atıf
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Yaygın Kullanılan Dozajlar
- general:
- 250-500 mg/day (equivalent to 5-10 billion CFU)
- aadprevention:
- 500 mg/day (start with antibiotic, continue 7 days after)
- cdiffprevention:
- 500 mg twice daily as adjunct to standard therapy
- travelersdiarrhea:
- 250-500 mg/day starting 5 days before travel
Üst sınır: Well-tolerated up to 1,000 mg/day in clinical trials
Araştırmalarda İncelenen Dozajlar
| Dozaj | Süre | Etki | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | 8 weeks | Positive | 47 |
| None | -- | Positive | -- |
| None | -- | Mixed | 279 |
| None | 16 weeks | Positive | 70 |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
En iyi alım zamanı: Can be taken with or without food; space 2 hours from antifungals
Safety & Side Effects
Bildirilen Yan Etkiler
- ⚠ Mild gas and bloating
- ⚠ Rare: fungemia in critically ill patients with central venous catheters
- ⚠ Thirst (yeast may increase water requirements)
- ⚠ Very rare: potential environmental contamination risk in ICU settings
Bilinen Etkileşimler
- ● Antifungal medications (may kill S. boulardii, reducing effectiveness)
- ● Monoamine oxidase inhibitors (S. boulardii contains tyramine)
- ● Immunosuppressants (theoretical risk of fungemia in immunocompromised patients)
Tolere edilebilir üst alım: Well-tolerated up to 1,000 mg/day in clinical trials
Herhangi bir takviye kullanmaya başlamadan önce mutlaka sağlık uzmanınıza danışın.Herhangi bir takviye başlatmadan önce her zaman sağlık uzmanınıza danışın.
Frequently Asked Questions
Does Saccharomyces boulardii help with Traveler's Diarrhea?
Based on 4 studies with 3,200 participants, there is moderate evidence from clinical studies that Saccharomyces boulardii may support Traveler's Diarrhea management. Our evidence grade is B (Good Evidence).
How much Saccharomyces boulardii should I take for Traveler's Diarrhea?
Studies have used various dosages. A commonly studied range is 250-500 mg/day (equivalent to 5-10 billion CFU). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Saccharomyces boulardii?
Reported side effects may include Mild gas and bloating, Rare: fungemia in critically ill patients with central venous catheters, Thirst (yeast may increase water requirements), Very rare: potential environmental contamination risk in ICU settings. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Saccharomyces boulardii and Traveler's Diarrhea?
We rate the evidence as Grade B (Good Evidence). This rating is based on 4 peer-reviewed studies with 3,200 total participants. The overall direction of effect is positive.
Related Evidence
Şu durum için diğer içerikler: Traveler's Diarrhea
Saccharomyces boulardii diğer sağlık durumları için
FDA Sorumluluk Reddi: Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.